2023
Aligning public health and public safety: Probation as a touchpoint to identify and link patients with opioid use disorder to opioid agonist treatment
Bromberg D, Galvez de Leon S, Litz T, Azbel L, Liberman A, Polonsky M, Dvoriak S, Saichuk N, Taxman F, Altice F. Aligning public health and public safety: Probation as a touchpoint to identify and link patients with opioid use disorder to opioid agonist treatment. PLOS Global Public Health 2023, 3: e0002349. PMID: 37910486, PMCID: PMC10619786, DOI: 10.1371/journal.pgph.0002349.Peer-Reviewed Original ResearchCriminal justice settingsOpioid use disorderBrief interventionUse disordersPrevalence of OUDProbation centersHIV prevention effortsJustice settingsMental healthHigh rateCommunity supervision settingsOAT servicesSBIRT interventionAgonist therapyHIV testingOpioid dependenceAgonist treatmentConsecutive individualsTreatment strategiesGeneral populationProbationSBIRTPrevention effortsSupervision settingParticipantsModelling the impact and cost‐effectiveness of non‐governmental organizations on HIV and HCV transmission among people who inject drugs in Ukraine
Stone J, Trickey A, Walker J, Bivegete S, Semchuk N, Sazonova Y, Varetska O, Altice F, Saliuk T, Vickerman P. Modelling the impact and cost‐effectiveness of non‐governmental organizations on HIV and HCV transmission among people who inject drugs in Ukraine. Journal Of The International AIDS Society 2023, 26: e26073. PMID: 37012669, PMCID: PMC10070931, DOI: 10.1002/jia2.26073.Peer-Reviewed Original ResearchConceptsAntiretroviral therapyHepatitis C virusHCV incidenceHCV infectionHIV/HCV testingHIV/HCV infectionHCV transmission modelNeedles/syringesHCV testingHCV eliminationHCV transmissionAgonist treatmentC virusNew HIVHigh prevalencePWIDHIVCondom useSubstantial detrimental impactInfectionIncidencePreventative impactDrugsCoverage levelsDALYs
2022
Health-related quality of life in people receiving opioid agonist treatment and treatment for hepatitis C virus infection
Dalgard O, Litwin AH, Shibolet O, Grebely J, Nahass R, Altice FL, Conway B, Gane EJ, Luetkemeyer AF, Peng CY, Iser D, Gendrano IN, Kelly MM, Haber BA, Platt H, Puenpatom A. Health-related quality of life in people receiving opioid agonist treatment and treatment for hepatitis C virus infection. Journal Of Addictive Diseases 2022, 41: 213-224. PMID: 35920743, DOI: 10.1080/10550887.2022.2088978.Peer-Reviewed Original ResearchConceptsElbasvir/grazoprevirHepatitis C virus infectionC virus infectionOpioid agonist therapyHealth-related qualityEnd of treatmentHCV infectionAgonist therapyVirus infectionChronic hepatitis C virus (HCV) infectionImproved health-related qualityMental component summary scoresTreatment week 4Placebo-controlled studyOpioid agonist treatmentMedical Outcomes StudyComponent summary scoresSF-36v2 scoresTreatment differencesImproved HRQOLViral eradicationActing antiviralsOpioid dependenceAgonist treatmentGeneral health
2021
Modelling the intervention effect of opioid agonist treatment on multiple mortality outcomes in people who inject drugs: a three-setting analysis
Stone J, Degenhardt L, Grebely J, Larney S, Altice FL, Smyrnov P, Rahimi-Movaghar A, Alavi M, Young AM, Havens JR, Miller WC, Hickman M, Vickerman P. Modelling the intervention effect of opioid agonist treatment on multiple mortality outcomes in people who inject drugs: a three-setting analysis. The Lancet Psychiatry 2021, 8: 301-309. PMID: 33640039, PMCID: PMC8255389, DOI: 10.1016/s2215-0366(20)30538-1.Peer-Reviewed Original ResearchConceptsOpioid agonist treatmentDrug-related deathsOAT coverageDrug-related harmAgonist treatmentHepatitis C virus transmissionC virus transmissionOverall health benefitsUK National InstituteNational InstituteHIV 0OAT retentionHIV mortalityInjury 3Opioid dependenceMortality outcomesUS National InstitutesHCV-2Overdose deathsSignificant additional effectIntervention effectsDrug abuseHealth benefitsMortalityDeath
2019
Cost‐effectiveness of expanding the capacity of opioid agonist treatment in Ukraine: dynamic modeling analysis
Morozova O, Crawford FW, Cohen T, Paltiel AD, Altice FL. Cost‐effectiveness of expanding the capacity of opioid agonist treatment in Ukraine: dynamic modeling analysis. Addiction 2019, 115: 437-450. PMID: 31478285, PMCID: PMC7015766, DOI: 10.1111/add.14797.Peer-Reviewed Original ResearchConceptsOpioid agonist treatmentOpioid use disorderOAT coverageAgonist treatmentGross domestic productOpioid use initiationOpioid addiction epidemicOAT accessHIV epidemicUse disordersAddiction epidemicCapita gross domestic productPay thresholdsTreatment demandUse initiationAddiction treatmentIncremental costBaseline capacityTreatmentPotential peer effectsDomestic productTreatment spilloversEpidemicPeer effectsCoverage levelsGlobal patterns of opioid use and dependence: harms to populations, interventions, and future action
Degenhardt L, Grebely J, Stone J, Hickman M, Vickerman P, Marshall BDL, Bruneau J, Altice FL, Henderson G, Rahimi-Movaghar A, Larney S. Global patterns of opioid use and dependence: harms to populations, interventions, and future action. The Lancet 2019, 394: 1560-1579. PMID: 31657732, PMCID: PMC7068135, DOI: 10.1016/s0140-6736(19)32229-9.Peer-Reviewed Original ResearchConceptsOpioid agonist treatmentOpioid useExtramedical opioid useIllicit opioid useRisk Factor StudyHepatitis C virusDrug-related harmRange of interventionsHIV mortalityOverall mortalityAgonist treatmentExtramedical usePatient acceptabilityC virusHigh prevalenceOpioid overdoseHigh-income countriesGlobal burdenOpioidsMultiple healthEffective interventionsInterventionTreatment qualityDrugsHIVTreating opioid dependence with extended-release naltrexone (XR-NTX) in Ukraine: Feasibility and three-month outcomes
Makarenko I, Pykalo I, Springer SA, Mazhnaya A, Marcus R, Filippovich S, Dvoriak S, Altice FL. Treating opioid dependence with extended-release naltrexone (XR-NTX) in Ukraine: Feasibility and three-month outcomes. Journal Of Substance Use And Addiction Treatment 2019, 104: 34-41. PMID: 31370983, PMCID: PMC8215516, DOI: 10.1016/j.jsat.2019.05.008.Peer-Reviewed Original ResearchConceptsOpioid use disorderOpioid agonist treatmentXR-NTX injectionXR-NTX treatmentXR-NTXUrine drug testingOpioid useExtended-release naltrexoneMonths of treatmentThree-month outcomeHealth-related qualityAdverse side effectsSymptoms of depressionOpioid dependenceAgonist treatmentLife scoresTreatment optionsIndependent factorsSide effectsUse disordersPeriod of observationDrug useStimulant useTreatment motivationDrug testing
2018
Opioid Agonist Treatment and Improved Outcomes at Each Stage of the HIV Treatment Cascade in People Who Inject Drugs in Ukraine
Mazhnaya A, Marcus R, Bojko MJ, Zelenev A, Makarenko I, Pykalo I, Filippovych S, Dvoriak S, Altice FL. Opioid Agonist Treatment and Improved Outcomes at Each Stage of the HIV Treatment Cascade in People Who Inject Drugs in Ukraine. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2018, 79: 288-295. PMID: 30312275, PMCID: PMC8215524, DOI: 10.1097/qai.0000000000001827.Peer-Reviewed Original ResearchConceptsOpioid agonist treatmentHIV treatment cascadeTreatment cascadeAgonist treatmentIndependent factorsHepatitis C virus testingOpioid-dependent PWIDOpioid use disorderClinical care settingsLogistic regression modelsOAT coverageAntiretroviral therapyHIV careUNAIDS 90HIV preventionImproved outcomesTreatment strategiesCare settingsVirus testingNationwide studyPWIDUse disordersOAT expansionHIVCareDrug injection within prison in Kyrgyzstan: elevated HIV risk and implications for scaling up opioid agonist treatments
Azbel L, Wegman MP, Polonsky M, Bachireddy C, Meyer J, Shumskaya N, Kurmanalieva A, Dvoryak S, Altice FL. Drug injection within prison in Kyrgyzstan: elevated HIV risk and implications for scaling up opioid agonist treatments. International Journal Of Prisoner Health 2018, 14: 175-187. PMID: 30274558, PMCID: PMC6447033, DOI: 10.1108/ijph-03-2017-0016.Peer-Reviewed Original ResearchConceptsMethadone maintenance treatmentNeedle syringe programsDrug injectionDrug injectorsHigh HIV risk behaviorElevated HIV riskPrison drug injectionHepatitis C infectionOpioid agonist treatmentHIV risk behaviorsC infectionHIV incidenceAgonist treatmentMaintenance treatmentIndependent correlatesBiobehavioral surveysHIV riskOnly examinationRisk behaviorsMMT useLow uptakeCurrent incarcerationInjectionLogit linkHigh-risk environmentsAssessment of barrier severity and willingness to enter opioid agonist treatment among people who inject drugs in Ukraine
Zelenev A, Shea P, Mazhnaya A, Rozanova J, Madden L, Marcus R, Altice FL. Assessment of barrier severity and willingness to enter opioid agonist treatment among people who inject drugs in Ukraine. Drug And Alcohol Dependence 2018, 190: 82-88. PMID: 29990648, PMCID: PMC6292439, DOI: 10.1016/j.drugalcdep.2018.05.027.Peer-Reviewed Original ResearchConceptsOpioid agonist therapyOpioid agonist treatmentOpioid-dependent peopleSubstance abuse treatment programsCross-sectional surveyAgonist therapyAgonist treatmentHIV preventionTreatment perceptionsTreatment efficacyOAT expansionStudy participantsTreatment programAddiction treatmentComposite measureSeveritySocial stigmaDrugsTreatmentStructural barriersBarrier severityParticipantsPerceptions of Health-Related Community Reentry Challenges among Incarcerated Drug Users in Azerbaijan, Kyrgyzstan, and Ukraine
Rozanova J, Morozova O, Azbel L, Bachireddy C, Izenberg JM, Kiriazova T, Dvoryak S, Altice FL. Perceptions of Health-Related Community Reentry Challenges among Incarcerated Drug Users in Azerbaijan, Kyrgyzstan, and Ukraine. Journal Of Urban Health 2018, 95: 508-522. PMID: 29728898, PMCID: PMC6095752, DOI: 10.1007/s11524-018-0256-4.Peer-Reviewed Original ResearchConceptsOpioid agonist treatmentSubstance use disordersUse disordersMethadone treatmentDrug usersPoor general healthGeneral health conditionPerception of healthAgonist treatmentDrug injectionGeneral healthHigh prevalenceHealth needsHealth-related tasksLogistic regressionMethadoneHealth conditionsPre-release planningDisordersTreatmentPublic healthTotal samplePrison settingDrugsHealthConcurrent drug injection during opioid agonist treatment among people who inject drugs in Ukraine
Makarenko I, Mazhnaya A, Marcus R, Pykalo I, Madden L, Filippovich S, Dvoriak S, Altice FL. Concurrent drug injection during opioid agonist treatment among people who inject drugs in Ukraine. Journal Of Substance Use And Addiction Treatment 2018, 87: 1-8. PMID: 29471921, PMCID: PMC5826566, DOI: 10.1016/j.jsat.2018.01.007.Peer-Reviewed Original ResearchConceptsOpioid agonist treatmentMethadone maintenance treatmentConcurrent illicit drug useOAT patientsIllicit drug useDrug injectionDrug useAgonist treatmentUse disordersMultivariable logistic regressionConcurrent drug useOngoing drug usePolysubstance use disorderAlcohol use disorderMaintenance treatmentIndependent correlatesBMT programSevere opioidDrug injectingPatientsHealth outcomesTreatment dropoutAlcohol dependenceInjection initiationYounger age
2017
Retention in medication-assisted treatment programs in Ukraine—Identifying factors contributing to a continuing HIV epidemic
Dumchev K, Dvoryak S, Chernova O, Morozova O, Altice FL. Retention in medication-assisted treatment programs in Ukraine—Identifying factors contributing to a continuing HIV epidemic. International Journal Of Drug Policy 2017, 48: 44-53. PMID: 28800420, PMCID: PMC5603251, DOI: 10.1016/j.drugpo.2017.05.014.Peer-Reviewed Original ResearchConceptsOpioid agonist treatmentMedication-assisted treatment programTB test resultsTwelve-month retentionCare delivery systemCorrelates of retentionEvidence-based strategiesTB patientsMultivariable analysisOpioid dependenceAgonist treatmentHIV transmissionClinical recordsHIV epidemicOAT programsPatient retentionHigher dosingHigh dosesTreatment programPatientsSurvival analysis methodsDosingTuberculosisElectronic monitoring systemTreatmentWillingness to pay for opioid agonist treatment among opioid dependent people who inject drugs in Ukraine
Makarenko I, Mazhnaya A, Marcus R, Bojko MJ, Madden L, Filippovich S, Dvoriak S, Altice FL. Willingness to pay for opioid agonist treatment among opioid dependent people who inject drugs in Ukraine. International Journal Of Drug Policy 2017, 45: 56-63. PMID: 28628853, PMCID: PMC5533603, DOI: 10.1016/j.drugpo.2017.05.037.Peer-Reviewed Original ResearchConceptsOpioid agonist treatmentOpioid-dependent peopleAgonist treatmentCurrent opioid agonist treatmentCross-sectional nationwide surveyMonthly incomeMultivariate logistic regressionIndependent predictorsPWIDKruskal-Wallis testPsychosocial counselingPrevious unsuccessful attemptsYounger ageLogistic regressionDependent peopleHigher incomeOne-way ANOVANationwide surveyDrugsContinuous variablesFamily supportTreatmentLarge percentageBetter accessPrimary healthcare-based integrated care with opioid agonist treatment: First experience from Ukraine
Morozova O, Dvoriak S, Pykalo I, Altice FL. Primary healthcare-based integrated care with opioid agonist treatment: First experience from Ukraine. Drug And Alcohol Dependence 2017, 173: 132-138. PMID: 28242537, PMCID: PMC5545131, DOI: 10.1016/j.drugalcdep.2016.12.025.Peer-Reviewed Original ResearchMeSH KeywordsAdultBuprenorphineCross-Sectional StudiesDelivery of Health Care, IntegratedFemaleHealth Services ResearchHIV InfectionsHumansMaleMethadoneMiddle AgedOpiate Substitution TreatmentOpioid-Related DisordersPatient DropoutsPatient SatisfactionPilot ProjectsPrimary Health CareQuality of LifeSubstance Abuse, IntravenousUkraineConceptsOpioid agonist therapyPrimary healthcare clinicsIntegrated carePHC staffHIV patientsHIV epidemicOAT patientsOpioid agonist treatmentStandard of careAddiction treatment settingsAgonist therapyObservational cohortMiddle-income countriesAgonist treatmentPrimary careComprehensive healthcare servicesPWIDHealthcare clinicsAddiction clinicPatientsTreatment settingsDrug usersPilot studyCareHealthcare services
2016
Determinants of willingness to enroll in opioid agonist treatment among opioid dependent people who inject drugs in Ukraine
Makarenko I, Mazhnaya A, Polonsky M, Marcus R, Bojko MJ, Filippovych S, Springer S, Dvoriak S, Altice FL. Determinants of willingness to enroll in opioid agonist treatment among opioid dependent people who inject drugs in Ukraine. Drug And Alcohol Dependence 2016, 165: 213-220. PMID: 27370527, PMCID: PMC5094181, DOI: 10.1016/j.drugalcdep.2016.06.011.Peer-Reviewed Original ResearchConceptsOpioid agonist treatmentAdjusted odds ratioOpioid use disorderAgonist treatmentUse disordersSignificant adjusted odds ratiosMultivariable logistic regressionHIV-negative statusPatient-level interventionsOpioid-dependent peopleInjection frequencyHIV statusOdds ratioRecent overdoseIndependent factorsPWIDLogistic regressionPrevious imprisonmentHigher injection frequencySignificant correlatesPrior incarcerationFamily supportDisordersDrugsIntervention
2014
Design and methods of a double blind randomized placebo-controlled trial of extended-release naltrexone for HIV-infected, opioid dependent prisoners and jail detainees who are transitioning to the community
Di Paola A, Lincoln T, Skiest DJ, Desabrais M, Altice FL, Springer SA. Design and methods of a double blind randomized placebo-controlled trial of extended-release naltrexone for HIV-infected, opioid dependent prisoners and jail detainees who are transitioning to the community. Contemporary Clinical Trials 2014, 39: 256-268. PMID: 25240704, PMCID: PMC4283549, DOI: 10.1016/j.cct.2014.09.002.Peer-Reviewed Original ResearchConceptsOpioid agonist treatmentPlacebo-controlled trialXR-NTXAgonist treatmentOpioid dependenceTreatment outcomesPoor HIV treatment outcomesOpioid treatment outcomesOpioid-dependent prisonersExtended-release naltrexoneHIV treatment outcomesHIV transmission riskEvidence-based treatmentsCriminal justice settingsEarly acceptabilityStudy medicationFirst injectionStudy acceptabilityHIVTotal referralsJail detaineesCommunity settingsTransmission riskDrug relapseHigh internal validity